mutation in different haematopoietic lineages are markedly distinct. BRAF(V600E) expression in HSCs can cause a tumoural disease, but results in a neurodegenerative inflammatory disorder when ...

In this interview, Vernon Sondak, MD, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the brain or other sites.

BRAF mutations are also found in 40 to 70% of papillary or anaplastic thyroid cancers 6–8,16 ... Stable disease was defined as the absence of shrinkage sufficient for a partial response and ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

(PhysOrg.com) -- Research has added to the evidence that a genetic mutation found in over 60 per cent of malignant melanomas is an important target for drugs to treat the disease.

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.

BRAF V600E mutations occur in 8-12% of mCRCs, and it has emerged as a distinct subtype marked by a very poor prognosis ...

It is a niche indication, given that BRAF mutations are estimated to occur in just 8% to 10% of people with metastatic colorectal cancer, but an important development for patients as these tumours ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC. ... this subpopulation of patients exhibits a risk of mortality double that of patients with no known BRAF mutation.